Other
Oligohydramnios
7
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Oligohydramnios is an early-stage landscape with 7 programs across 4 companies. The most active players are Omnivium, Viatris Specialty LLC, Mario Negri Institute for Pharmacological Research. 2 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 23
Analysis
Trial Status
7
clinical trials
Terminated2 · 29%
Completed2 · 29%
Unknown status2 · 29%
Recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Nitric Oxide Donors for Treatment of Isolated Oligohydramnios
Completed·—·Phase 2/3·NCT02712125·100 enrolled
Sildenafil Citrate Therapy for Oligohydramnios
Unknown status·—·N/A·NCT02372487·184 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)